Ticagrelor of Net Clinical Benefit aAfter Stroke, TIA: THALES Ticagrelor of Net Clinical Benefit aAfter Stroke, TIA: THALES
A new analysis of data from the THALES trial separates out the reduction in ischemic events from the increase in bleeding events and shows the benefit outweighs the risk in a ratio of four-to-one.Medscape Medical News
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news
More News: Bleeding | Brain | Internal Medicine | Ischemic Stroke | Neurology | Neurosurgery | Stroke